JAN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-0.360.0% YoY
Profit margin-0.0%REAL ESTATE
Market cap$5.42BMid cap
Wall Street coverage
$29.91median target· current $22.89 (+30.7%)11 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.50
- P/S (TTM)
- 8.26
- EV/EBITDA
- 21.22
Profitability & growth
- ROE (TTM)
- 0.5%
- Operating margin
- 0.5%
- Revenue growth YoY
- 34.5%
- Dividend yield
- 0.1%
- Beta
- —
Last earnings
May 6, 2026 · Estimate $0.09 · Reported $0.01
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Janus Living, Inc.
Company profileJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.
Classification
- Sector
- Real Estate
- Industry
- Reit - Residential
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 4600 SOUTH SYRACUSE STREET, DENVER, CO
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$5.42B
Shares outstanding$212.2M
52W high$28.34
52W low$22.62
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent